Isovaleric Acid
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Short-chain branched fatty acid (leucine catabolism intermediate) |
| Molecular Formula / CAS | C₅H₁₀O₂ · CAS 503-74-2 |
| Primary Botanical Source(s) | Valeriana officinalis and related Valeriana species (as a volatile decomposition product); also present in fermented and aged foods |
| Plant Part | Root/rhizome (valerian) — forms during drying and storage rather than existing at fixed levels in fresh root |
| Typical Content | A volatile constituent responsible for valerian’s characteristic pungent odour, formed progressively as the root dries; not the analytical marker used for valerian standardisation |
| Solubility / Format | Volatile short-chain fatty acid; not isolated or formulated as a standalone botanical ingredient |
| Sourcing Status | Informational-only — distinct from the valerenic-acid marker Herbuno’s standardised valerian products use |
| Buy from Herbuno | Not applicable — see HerbIQ Compound Index for valerenic-acid-standardised valerian ingredients |
Name origin: Isovaleric acid takes its name from valerian (Valeriana officinalis), the root from which it was historically isolated and characterised, though the compound is now recognised as far more widely distributed — it also occurs in fermented dairy, aged cheese, and as a normal human metabolic intermediate. Traditional use: Isovaleric acid itself was never used as an isolated preparation; it is more accurately understood as one of several volatile compounds that accumulate as valerian root dries and its essential oil fraction degrades, contributing to the root’s distinctive, strong odour that traditional preparations relied on as a rough quality and freshness indicator. Research trajectory: Early 20th-century phytochemistry attributed part of valerian’s sedative reputation to isovaleric acid and related volatile constituents, but subsequent pharmacological research has shifted attribution firmly toward valerenic acid as the principal GABA(A)-receptor-active constituent responsible for valerian’s calming effects, with isovaleric acid now understood as a secondary, non-standardised volatile rather than the plant’s primary active marker. Separately, isovaleric acid has become clinically significant as the accumulating metabolite in isovaleric acidemia, a rare inherited disorder of leucine metabolism. Safety context: Isovaleric acid is not a controlled substance, but it carries an important clinical association that formulators should be aware of: elevated isovaleric acid is the defining biochemical marker of isovaleric acidemia, a genetic metabolic disorder, which is why this page is documented informational-only rather than presented as a wellness-oriented sourcing option.
Evidence for Isovaleric Acid Applications
Isovaleric acid is a short-chain branched fatty acid that, in the human body, forms as a normal intermediate in the mitochondrial catabolism of the branched-chain amino acid leucine, via conversion of isovaleryl-CoA by the enzyme isovaleryl-CoA dehydrogenase. In valerian root, a chemically analogous compound forms as part of the volatile oil fraction, becoming more concentrated as the root dries and its labile valepotriate and essential-oil constituents break down — the strong, distinctive valerian smell familiar to anyone who has handled the dried root is substantially attributable to isovaleric acid. Claim strength: Moderate.
Historical pharmacognosy literature grouped isovaleric acid among valerian’s potentially sedative volatile constituents, alongside valepotriates and other essential-oil components, and some sources describe it as interacting weakly with GABAergic signalling pathways. However, modern pharmacological research on valerian’s sedative and anxiolytic mechanism has concentrated almost entirely on valerenic acid, a structurally distinct sesquiterpene, as the principal GABA(A)-receptor-modulating constituent; isovaleric acid does not carry comparable dedicated clinical or mechanistic research support and is not the compound behind current valerian standardisation practice. Claim strength: Emerging.
The clinically significant literature on isovaleric acid concerns isovaleric acidemia (IVA), a rare, autosomal recessive inborn error of leucine metabolism caused by deficiency of the enzyme isovaleryl-CoA dehydrogenase. This deficiency causes isovaleric acid and its derivatives to accumulate in the blood and urine, producing a characteristic “sweaty feet” odour during acute metabolic episodes and, without treatment, potentially severe complications including metabolic acidosis, hyperammonaemia and, in acute neonatal presentations, life-threatening metabolic crisis (Mütze et al.). IVA was the first organic acidemia disorder recognised in humans and remains a standard component of newborn metabolic screening panels in many countries. Claim strength: High (established clinical genetics).
Documented clinical case literature illustrates the range of IVA presentation, from severe neonatal metabolic crisis to milder, chronic intermittent forms diagnosed later in childhood, with management centred on dietary leucine restriction and carnitine or glycine supplementation to support isovaleryl-CoA clearance (et al. 2022). A broader review of IVA genetic and phenotypic heterogeneity notes that early diagnosis through newborn screening and dietary management have substantially improved outcomes for affected individuals compared to historical presentation patterns (Ensenauer et al.). Claim strength: High (established clinical genetics).
For formulation purposes, the practical takeaway is that isovaleric acid is not the compound that valerian-based botanical ingredients are or should be standardised to, and its clinical association with a genetic metabolic disorder makes it inappropriate to position as a wellness or supplement-relevant compound in its own right, distinct from its incidental presence as a volatile constituent of aged valerian root material. Claim strength: Moderate.
Dosage & Formulator Specification
Isovaleric acid is not formulated or supplied as a standalone ingredient by any commercial botanical supplier, and no supplemental dosing precedent exists for it independent of whole valerian root material, where it occurs as a volatile, unstandardised trace constituent rather than a controlled formulation input.
Clinically, isovaleric acid is monitored and quantified in diagnostic contexts — via tandem mass spectrometry newborn screening panels measuring isovalerylcarnitine (C5-acylcarnitine), and via urine organic acid analysis measuring isovalerylglycine — rather than through the HPLC or GC methods used for standard botanical marker-compound quality control.
Formulators sourcing valerian material for its documented sedative research should specify valerenic-acid-standardised extract material and request HPLC certificates of analysis confirming valerenic acid content specifically, rather than relying on aroma intensity as an informal quality proxy; while a stronger valerian odour does correlate loosely with isovaleric acid and related volatile content, it is not a reliable indicator of valerenic acid concentration, which is the pharmacologically relevant marker.
No regulatory limit applies to isovaleric acid within standard valerian botanical ingredients, since it is a naturally occurring trace volatile rather than an added or process-derived contaminant. Formulators should not reference isovaleric acid in product marketing or labelling given its clinical association with a named genetic disorder, which could create confusing or inappropriate associations for consumers unfamiliar with the distinction between dietary trace exposure and the inherited enzyme deficiency.
Frequently Asked Questions — Isovaleric Acid
No. Valerian’s documented sedative research centres on valerenic acid, a structurally distinct sesquiterpene, which is the compound standardised valerian extracts — including Herbuno’s Valerenic Acids 1% and 0.8% Powder — are calibrated to. Isovaleric acid is a separate, unstandardised volatile constituent responsible mainly for valerian’s characteristic strong odour.
Isovaleric acidemia (IVA) is a rare, inherited metabolic disorder caused by deficiency of the enzyme isovaleryl-CoA dehydrogenase, which normally helps break down the amino acid leucine. The resulting build-up of isovaleric acid and related metabolites can cause a characteristic odour and, without treatment, serious metabolic complications; it is typically identified through newborn screening.
The characteristic strong odour of dried valerian root is substantially attributable to isovaleric acid, which forms progressively as the root dries and its volatile oil and valepotriate constituents break down. This means aroma intensity relates more to drying and storage than to the valerenic acid content that determines the extract’s pharmacological standardisation.
Isovaleric acid is not the compound Herbuno’s valerian ingredients are standardised to, and it carries a clinical association with a named genetic disorder that makes it inappropriate to position as a wellness-relevant sourcing target. This page documents its chemistry and clinical context factually rather than as a product offering.
Related compounds: Angelic Acid, Ligustilide